PHIBRO ANIMAL HEALTH CORP

PHIBRO ANIMAL HEALTH CORP

Phibro Animal Health Corp (PAHC) is a mid-cap company focused on animal health, mineral nutrition and performance solutions for livestock and companion animals. Investors should know it supplies vaccines, feed additives and pharmaceutical products alongside technical services to farmers, integrators and distributors. Its performance is tied to global demand for protein, livestock herd sizes and feed input costs, and it has exposure to emerging markets where growth in meat and dairy consumption can be faster. Profitability can be sensitive to commodity cycles, regulatory approvals and competitive pressures from larger animal-health groups. With a market capitalisation around $1.7bn, PAHC may appeal to investors seeking sector-specific exposure rather than diversified healthcare coverage. Consider this as an educational overview: values can rise and fall, past performance does not predict the future, and this is not personalised investment advice. Review company reports, recent results and sector peers before making decisions.

Stock Performance Snapshot

Hold

Analyst Rating

Analysts suggest holding Phibro Animal Health's stock with a target price of $43, indicating limited growth.

Above Average

Financial Health

Phibro Animal Health Corp shows strong revenue and cash flow, indicating solid financial performance.

Below Average

Dividend

Phibro Animal Health's dividend yield of 0.88% is lower than many investors prefer. If you invested $1000 you would be paid $8.80 a year in dividends (based on the last 12 months).

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Discover More Opportunities

ABBV

AbbVie

Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.

AMGN

AMGEN INC

Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.

APLS

APELLIS PHARMACEUTICALS INC

Apellis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases.

Baskets Featuring PAHC

Next-Gen Proteins

Next-Gen Proteins

Looking to invest in the future of food? This carefully selected group of stocks represents companies solving our global protein challenges. From plant-based alternatives to agricultural innovation, these stocks have been thoughtfully chosen by our analysts for their potential in this growing market.

Published: June 17, 2025

Explore Basket
Pets Are Family

Pets Are Family

The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

πŸ“ˆ

Livestock demand story

Global demand for meat and dairy can support sales of vaccines and feed additives, though results vary with commodity cycles and herd sizes.

🌍

Emerging market exposure

Sales growth may come from faster-expanding markets abroad, but exposure brings currency, regulatory and distribution risks.

⚑

Innovation and approvals

New product development and regulatory clearances can drive revenue, yet R&D and approval timing add uncertainty to earnings.

Why invest with Nemo?

Nemo Logo Fade
πŸ†“

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

πŸ”’

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

πŸ’°

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Frequently asked questions